NRX PharmaceuticalsNRXP
13F holders, Q2 2024 (June 30)19holders
$2.47avg. 13F price*
At the end of Q2 2024, 19 institutions reported holding NRX Pharmaceuticals Inc. (NRXP) in their 13F filings. The largest holders were Vanguard Group Inc. ($586K), AdvisorShares Investments LLC ($279K) and Geode Capital Management, LLC ($160K).
- Company
- NRX Pharmaceuticals Inc.
- CUSIP
- 629444209
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 20 | $1.3M |
| Exits | 0 | $0 |
Ownership 19 holders
| Vanguard Group Inc. | 0.00% | New | 240,316 | $586K |
| AdvisorShares Investments LLC | 0.05% | New | 108,085 | $279K |
| Geode Capital Management, LLC | 0.00% | New | 65,659 | $160K |
| BlackRock Inc. | 0.00% | New | 29,075 | $71K |
| Virtu Financial LLC | 0.00% | New | 17,043 | $42K |
| State Street Corp. | 0.00% | New | 16,724 | $41K |
| One Wealth Management Investment & Advisory Services, LLC | 0.01% | New | 15,041 | $37K |
| National Philanthropic Trust | 0.00% | New | 10,050 | $25K |
| Morgan Stanley | 0.00% | New | 4,396 | $11K |
| Royal Bank of Canada | 0.00% | New | 4,013 | $10K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 3,327 | $8K |
| Bank of America Corp. | 0.00% | New | 3,290 | $8K |
| Wells Fargo & Company | 0.00% | New | 1,500 | $4K |
| UBS Group AG | 0.00% | New | 1,087 | $3K |
| NewEdge Advisors, LLC | 0.00% | New | 583 | $1K |
| Qube Research & Technologies Ltd | 0.00% | New | 117 | $285 |
| Harbour Investments, Inc. | 0.00% | New | 47 | $115 |
| JPMorgan Chase & Co. | 0.00% | New | 34 | $83 |
| Larson Financial Group LLC | 0.00% | New | 22 | $54 |
"% of holder's portfolio" is NRXP's weight in each manager's 13F, not the share of NRX Pharmaceuticals Inc. the manager owns.